“…Canada has shown consistent leadership in its national efforts to promote impactful ELSI research into regenerative medicine, such as stem cell research, tissue engineering, and gene editing 1 , 2 . For example, since its launch in 2001, the $90 M CAD Stem Cell Network (SCN), has been a catalyst for the translation of stem cell research into clinical and commercial products, and for innovative programs in ethics, law, sociology, health economics, communications, and other societal developments in this rapidly evolving area 3 . Early successes included the establishment of a global policy database of regulations on somatic cell nuclear transfer and human embryonic stem cell research, legal scholarship into intellectual property, biobanking, confidentiality, consent, and extensive public outreach, and partnerships with organizations internationally 4 .…”